Urodelia, a French research company focused on the development of a therapeutic vaccine in oncology, is seeking to raise 2.5 million euros in 2019 to deploy its technology in veterinary oncology and fund human health research. Its needs 6 million euros over 3 years. Based on the expertise of founders-associates in calcium phosphates chemistry and more specifically hydroxyapatite, Urodelia has developed an autologous vaccine in veterinary medicine whose concept is based on the association between tumour proteins purified from a biopsy of the animal’s cancer cells and hydroxyapatite as a vector for immune stimulation.
About ten animal studies concerning about 15 different cancers have led to the confirmation of the effectiveness of the technology on pets’ overall survival improvement and of its total safety in more than 400 animals (dogs, cats, horses). Based on the results obtained in animals, Urodelia is now entering a decisive phase: the development of its autologous therapeutic vaccine in human oncology. With this in mind, Urodelia is entering a phase that requires raising funds to finance clinical trials in humans and find regulatory ways to market this vaccine. The company’s ambitious five-year strategy aims to access the market of human cancer treatments as well as the deployment of apa.vac® sales in veterinary medicine.
Nicole Rouquet, President of Urodelia, who has accompanied the research teams since their first work in orthopaedics, states «We are proud of the progress made since the very beginning and very excited to take this step that seemed so far away a few years ago. The uniqueness of our research has led us to face many challenges, both scientific and economic, at every stage. These challenges have strengthened our convictions. We still have to transform the perspectives opened up by research on animals with the hope of helping people affected by cancer and in a therapeutic impasse, due to their weak immune defenses. We are aware that France is a leading country in the quality of cancer care and our dearest wish is to contribute an additional breakthrough in French innovation and bolster this leading position.”
Urodelia has developed an autologous therapeutic vaccine combining proteins from tumor cells with hydroxyapatite.
This therapeutic vaccine, tested in animals, is now on the market in veterinary medicine under the name apa.vac®.
Today, more than 400 animals (dogs, cats, horses), covering 15 distinct pathologies, have been treated by apa.vac® since 2009.